Addition of plerixafor to imatinib does not improve survival or decrease disease burden of leukemic mice. (A) Kaplan-Meier survival analysis of mock-treated, plerixafor only, imatinib only, or imatinib + plerixafor treatment groups (P = .3228, log-rank test). The experiment was terminated at day 57. (B) FACS analysis for GFP to assess the proportion of leukemia cells in the peripheral blood. (C-D) Spleen and liver weights measured at necropsy. (E-F) Percentage GFP⁺ cells in spleen and bone marrow measured by FACS.